Astrazeneca PLC 6-K, filed Apr 29, 2020
Astrazeneca PLC (AZN)
6-K
2020-04-29
For: 2020-04-29
View Original
Added on
April 02, 2026
About this 6-K
Astrazeneca PLC filed this 6-K on April 29, 2020.
FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of April 2020
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca PLC
INDEX
TO EXHIBITS
1.
Result
of AGM
29 April 2020 16:00 BST
Results of Annual General Meeting held on 29 April
2020
AstraZeneca PLC announced the results of the voting at its Annual
General Meeting (AGM) today. As proposed in the Notice of AGM, all
Resolutions were decided by poll vote. Resolutions 10 - 13 were
passed as special resolutions; all other resolutions were passed as
ordinary resolutions.
|
|
RESOLUTION
|
VOTES FOR
|
% OF VOTES CAST
|
VOTES AGAINST
|
% OF VOTES CAST
|
VOTES CAST IN TOTAL
|
TOTAL VOTES CAST AS A % OF ISSUED SHARE CAPITAL
|
VOTES WITHHELD
|
|
1
|
To
receive the Company's Accounts, the Reports of the Directors and
Auditor and the Strategic Report for the year ended 31 December
2019
|
1,061,180,101
|
99.92
|
872,215
|
0.08
|
1,062,052,316
|
80.93%
|
7,121,452
|
|
2
|
To
confirm dividends
|
1,058,995,786
|
99.10
|
9,598,531
|
0.90
|
1,068,594,317
|
81.43%
|
579,469
|
|
3
|
To
reappoint PricewaterhouseCoopers LLP as Auditor
|
1,068,300,235
|
99.97
|
312,449
|
0.03
|
1,068,612,684
|
81.43%
|
560,776
|
|
4
|
To
authorise the Directors to agree the remuneration of the
Auditor
|
1,067,398,628
|
99.90
|
1,086,858
|
0.10
|
1,068,485,486
|
81.42%
|
687,961
|
|
5a
|
To
re-elect Leif Johansson as a Director
|
1,065,113,167
|
99.69
|
3,276,071
|
0.31
|
1,068,389,238
|
81.42%
|
784,805
|
|
5b
|
To
re-elect Pascal Soriot as a Director
|
1,067,248,723
|
99.90
|
1,033,124
|
0.10
|
1,068,281,847
|
81.41%
|
892,364
|
|
5c
|
To
re-elect Marc Dunoyer as a Director
|
1,060,164,242
|
99.25
|
8,056,265
|
0.75
|
1,068,220,507
|
81.40%
|
952,979
|
|
5d
|
To
re-elect Geneviève Berger as a Director
|
882,846,920
|
83.06
|
179,994,848
|
16.94
|
1,062,841,768
|
80.99%
|
6,331,650
|
|
5e
|
To
re-elect Philip Broadley as a Director
|
1,066,048,992
|
99.79
|
2,190,705
|
0.21
|
1,068,239,697
|
81.41%
|
933,713
|
|
5f
|
To
re-elect Graham Chipchase as a Director
|
1,062,682,507
|
99.48
|
5,520,936
|
0.52
|
1,068,203,443
|
81.40%
|
969,967
|
|
5g
|
To elect Michel
Demaré as a Director
|
1,066,252,259
|
99.82
|
1,969,593
|
0.18
|
1,068,221,852
|
81.40%
|
951,558
|
|
5h
|
To
re-elect Deborah DiSanzo as a Director
|
1,067,836,362
|
99.97
|
351,091
|
0.03
|
1,068,187,453
|
81.40%
|
985,957
|
|
5i
|
To
re-elect Sheri McCoy as a Director
|
1,064,329,862
|
99.64
|
3,890,368
|
0.36
|
1,068,220,230
|
81.40%
|
951,792
|
|
5j
|
To
re-elect Tony Mok as a Director
|
1,067,117,370
|
99.90
|
1,066,669
|
0.10
|
1,068,184,039
|
81.40%
|
989,371
|
|
5k
|
To
re-elect Nazneen Rahman as a Director
|
1,067,376,963
|
99.92
|
821,467
|
0.08
|
1,068,198,430
|
81.40%
|
973,592
|
|
5l
|
To
re-elect Marcus Wallenberg as a Director
|
955,082,665
|
89.42
|
113,060,725
|
10.58
|
1,068,143,390
|
81.40%
|
1,030,019
|
|
6
|
To
approve the Annual Report on Remuneration for the year ended 31
December 2019
|
1,032,308,145
|
96.65
|
35,747,783
|
3.35
|
1,068,055,928
|
81.39%
|
1,118,038
|
|
7
|
To
approve the Directors' Remuneration Policy
|
972,774,742
|
94.71
|
54,292,376
|
5.29
|
1,027,067,118
|
78.27%
|
42,106,679
|
|
8
|
To
authorise limited political donations
|
1,038,907,152
|
97.75
|
23,872,400
|
2.25
|
1,062,779,552
|
80.99%
|
6,394,668
|
|
9
|
To
authorise the Directors to allot shares
|
910,654,650
|
85.26
|
157,472,093
|
14.74
|
1,068,126,743
|
81.40%
|
1,046,979
|
|
10
|
To
authorise the Directors to disapply pre-emption rights
|
1,058,066,972
|
99.23
|
8,200,338
|
0.77
|
1,066,267,310
|
81.26%
|
2,906,339
|
|
11
|
To
authorise the Directors to further disapply pre-emption rights for
acquisitions and specified capital investments
|
1,054,711,677
|
98.92
|
11,513,414
|
1.08
|
1,066,225,091
|
81.25%
|
2,948,557
|
|
12
|
To
authorise the Company to purchase its own shares
|
1,051,131,060
|
98.41
|
16,950,800
|
1.59
|
1,068,081,860
|
81.39%
|
1,091,896
|
|
13
|
To
reduce the notice period for general meetings
|
998,062,805
|
93.44
|
70,101,553
|
6.56
|
1,068,164,358
|
81.40%
|
1,008,865
|
|
14
|
To
approve the 2020 Performance Share Plan
|
1,010,149,491
|
95.66
|
45,877,396
|
4.34
|
1,056,026,887
|
80.48%
|
13,147,356
|
Issued capital
As at 27 April 2020, the number of issued shares of the Company was
1,312,240,429 ordinary shares, which was the total number of shares
entitling the holders to attend and vote for or against all of the
resolutions at the AGM. In accordance with the Company's Articles
of Association, on a poll every member present in person or by
proxy has one vote for every share held.
AstraZeneca
AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development and commercialisation of prescription medicines,
primarily for the treatment of diseases in three therapy areas -
Oncology, Cardiovascular, Renal and Metabolism, and Respiratory.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries
and its innovative medicines are used by millions of patients
worldwide. Please visit astrazeneca.com and
follow the Company on Twitter @AstraZeneca.
Contacts
For details on how to contact the Investor Relations Team, please
click here.
For Media contacts, click here.
Adrian Kemp
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
AstraZeneca
PLC
|
Date:
29 April 2020
|
|
By: /s/
Adrian Kemp
|
|
|
Name:
Adrian Kemp
|
|
|
Title:
Company Secretary
|